Secreted ORF8 is a pathogenic cause of severe COVID-19 and is potentially targetable with select NLRP3 inhibitors
Xiaosheng Wu(Mayo Clinic), Thomas E. Witzig(WinnMed), Matthew J. Schellenberg(Mayo Clinic), Jonas Paludo(WinnMed), Jithma P. Abeykoon(Mayo Clinic), Vanessa Taupin(University of California San Diego), Taylor L. Witter(Mayo Clinic), Andrew D. Badley(Mayo Clinic), Michelle K. Manske(Mayo Clinic in Arizona), Haidong Dong(Mayo Clinic in Arizona), Kimberly Gwin(Mayo Clinic in Arizona), Yue Yu(Shanghai Ninth People's Hospital), Stephen M. Ansell(Mayo Clinic), Surendra Dasari(Mayo Clinic in Arizona), Xinyi Tang(Wuhan Third Hospital), Annie A. Wu(Johns Hopkins University), Gordon Ruan(Mayo Clinic in Arizona), Kevin E. Nowakowski(Mayo Clinic in Arizona), Vaishali Bhardwaj
Cited by 14
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k